TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2515524

Group type: EXPERIMENTAL
Intervention: Altretamine preparation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altretamine preparation 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Altretamine preparation 3 (control)
Number of subjects: 0
Study: 7253868

Group type: EXPERIMENTAL
Intervention: Post-blood trial after 920 ml equivalent of whole blood
Number of subjects: 12
Study: 31811339

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel dressing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline dressing (Control)
Number of subjects: 24
Study: 28658251

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Oral drug detected
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: No oral drug detected
Number of subjects: 224
Study: 26449801

Group type: EXPERIMENTAL
Intervention: Psycho-oncology training program (16 hours)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 96
Study: 25296623

Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch (21 mg every 24 hours)
Number of subjects: 341
Study: 22532189

Group type: EXPERIMENTAL
Intervention: High exposure at 6 W/kg (maxSAR10g in the head)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low exposure at 1.5 W/kg (maxSAR10g in the head)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control software for exposure monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure uncertainty analysis
Number of subjects: 0
Study: 20433806

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccination after topical application of imiquimod (250 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intradermal hepatitis B vaccination without imiquimod application (control group)
Number of subjects: 21
Study: 18760149

Group type: EXPERIMENTAL
Intervention: Intravenous BCAA supplementation (n=22; 19.6g/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (isonitrogenous; n=19)
Number of subjects: 41
Study: 15991648

Group type: EXPERIMENTAL
Intervention: Audio-CASI
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Self-administered questionnaires
Number of subjects: 1500
Study: 11910268

Group type: EXPERIMENTAL
Intervention: 20 mg ziprasidone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10625156

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD CPR)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 302
Study: 7725886

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2.5 mg/ml
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 32
Study: 2117190

Group type: EXPERIMENTAL
Intervention: Oxygen treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: No oxygen treatment
Number of subjects: 46
Study: 6679234

Group type: EXPERIMENTAL
Intervention: Terazosin hydrochloride (long-term therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terazosin hydrochloride (short-term therapy)
Number of subjects: 0
Study: 31150095

Group type: EXPERIMENTAL
Intervention: LB 133 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 31065885

Group type: EXPERIMENTAL
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 556

Group type: COMPARATOR
Intervention: Market prices for SICS
Number of subjects: 556

Group type: COMPARATOR
Intervention: Market prices for phacoemulsification
Number of subjects: 556
Study: 29016711

Group type: EXPERIMENTAL
Intervention: Drinks Meter
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: OneTooMany
Number of subjects: 402
Study: 26035185

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 25127173

Group type: EXPERIMENTAL
Intervention: LY2951742 (150 mg) subcutaneous injection every 2 weeks for 12 weeks
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo subcutaneous injection every 2 weeks for 12 weeks
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: LY2951742
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 22865902

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 305
Study: 19203562

Group type: EXPERIMENTAL
Intervention: CET + PSE (10 mg cetirizine and 120 mg pseudoephedrine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: CET (single treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: PSE (single treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 49
Study: 17680909

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) + pharmacotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 90
Study: 15169696

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day, with option to increase to 40 mg/day at week 4)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 174
Study: 11433064

Group type: EXPERIMENTAL
Intervention: 30 microgram of LD vaccine
Number of subjects: 4090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4090
Study: 9757887

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes plus oxytocin (2 IU injected plus 0.07 IU/min infused for 60 minutes)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes
Number of subjects: 7
Study: 8000461

Group type: EXPERIMENTAL
Intervention: Turning
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Back care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unassisted turning
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive range-of-motion exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anterior bath
Number of subjects: 30

Group type: COMPARATOR
Intervention: Order of interventions
Number of subjects: 30
Study: 3287685

Group type: EXPERIMENTAL
Intervention: Induction treatment with vincristine, prednisone, L‐asparaginase and rubidomycin (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Induction treatment with vincristine, prednisone and L‐asparaginase (Group A)
Number of subjects: 240
Study: 31135888

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 29570378

Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours before examination (Group 1, n = 1619)
Number of subjects: 3206

Group type: COMPARATOR
Intervention: Light meal before examination (Group 2, n = 1587)
Number of subjects: 3206
Study: 28118228

Group type: EXPERIMENTAL
Intervention: Procedure-specific Web-based educational module
Number of subjects: 65

Group type: COMPARATOR
Intervention: General patient safety Web-based educational module (Control)
Number of subjects: 65
Study: 25125488

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23289935

Group type: EXPERIMENTAL
Intervention: Group-based social skills training (SST) using the 12 weeks manualised SOSTA-FRA program
Number of subjects: 220

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 220
Study: 21431374

Group type: EXPERIMENTAL
Intervention: Measured gap resection technique (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gap balancing technique (Group B)
Number of subjects: 30
Study: 18496322

Group type: EXPERIMENTAL
Intervention: 500 mug of ipratropium bromide
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 15504429

Group type: EXPERIMENTAL
Intervention: Aggressive behavior monitoring using the overt aggression scale (OAS)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Psychopathology assessment using the positive and negative syndrome scale (PANSS)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Total PANSS scores
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: PANSS positive subscale scores
Number of subjects: 157
Study: 12707120

Group type: EXPERIMENTAL
Intervention: CPB group
Number of subjects: 71

Group type: COMPARATOR
Intervention: OPCAB group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CPB-DA group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study: 10561649

Group type: EXPERIMENTAL
Intervention: Successful external cephalic version
Number of subjects: 30

Group type: COMPARATOR
Intervention: Failed external cephalic version
Number of subjects: 30
Study: 8764356

Group type: EXPERIMENTAL
Intervention: Niravoline (2 mg dose, single 30-min i.v. infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niravoline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2063855

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO; 150 U/kg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO; 100 U/kg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO; 50 U/kg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 117
Study: 6355216

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 24
Study: 30497695

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate loading (400 mL, 2 hours before surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fasting (8 hours prior to surgery)
Number of subjects: 120
Study: 30290803

Group type: EXPERIMENTAL
Intervention: Hysteroscopic septum resection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 68
Study: 28299267

Group type: COMPARATOR
Intervention: Micromotor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 24998880

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg once-daily
Number of subjects: 931

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily
Number of subjects: 931
Study: 22730955

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Optimized treatment-as-usual (O-TAU)
Number of subjects: 63
Study: 20436354

Group type: EXPERIMENTAL
Intervention: Intervention (CVD risk reduction)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Rural group who decreased CVD risk
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Urban group who decreased CVD risk
Number of subjects: 388
Study: 17556623

Group type: EXPERIMENTAL
Intervention: Parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days
Number of subjects: 38
Study: 12939546

Group type: EXPERIMENTAL
Intervention: Rate control combined with antithrombotic therapy
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Rhythm control combined with antithrombotic therapy
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Quality of life scores
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Efficacy and safety of drugs used in treating AF
Number of subjects: 2600
Study: 10730228

Group type: EXPERIMENTAL
Intervention: 36 Gy radiation treatment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 10 Gy radiation treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no radiation treatment)
Number of subjects: 95
Study: 8931411

Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy (10 million U three times a week for 16 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (10 normal subjects)
Number of subjects: 47
Study: 1372126

Group type: EXPERIMENTAL
Intervention: 8 Gy
Number of subjects: 270

Group type: COMPARATOR
Intervention: 4 Gy
Number of subjects: 270
Study: 2860942

Group type: EXPERIMENTAL
Intervention: sulphapyridine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐aminosalicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: sulphasalazine
Number of subjects: 0
Study: 29583081

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 27005016

Group type: EXPERIMENTAL
Intervention: 100 kVp
Number of subjects: 80
Study: 24606612

Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 60601

Group type: EXPERIMENTAL
Intervention: Home birth with skilled birth attendant (SBA)
Number of subjects: 60601

Group type: COMPARATOR
Intervention: Home birth without skilled birth attendant (SBA)
Number of subjects: 60601
Study: 21506018

Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 21568143

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cyanoacrylate injection
Number of subjects: 150
Study: 19298038

Group type: EXPERIMENTAL
Intervention: Ultrasound navigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual pointer palpation
Number of subjects: 60
Study: 16023513

Group type: EXPERIMENTAL
Intervention: Plain soap with handwashing promotion
Number of subjects: 606

Group type: COMPARATOR
Intervention: Plain soap
Number of subjects: 606
Study: 12449403

Group type: EXPERIMENTAL
Intervention: Pulsatile cold compression (PCC) device applied to the ankle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Posterior molded splint
Number of subjects: 24
Study: 10355414

Group type: EXPERIMENTAL
Intervention: Off-pump coronary operation
Number of subjects: 22
Study: 7856782

Group type: EXPERIMENTAL
Intervention: Special Intervention group with a 12-session, 12-week smoking cessation program using nicotine gum
Number of subjects: 3923
Study: 2071783

Group type: EXPERIMENTAL
Intervention: 10 months of immunotherapy (IT) at 2 micrograms of Amb a I
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 22 months of immunotherapy (IT) at 24 micrograms of Amb a I
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 1 year of immunotherapy (IT) at 2 micrograms of Amb a I
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 2 years of immunotherapy (IT) at 2 micrograms of Amb a I
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 3 years of immunotherapy (IT) at 24 micrograms of Amb a I
Number of subjects: 79

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 79
Study: 6129719

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 320 mg per day for 6 to 31 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31117880

Group type: EXPERIMENTAL
Intervention: Navigation-assisted TKR
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional jig-based TKR
Number of subjects: 50
Study: 28416097

Group type: EXPERIMENTAL
Intervention: Presurgical nasoalveolar molding (PNAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no PNAM)
Number of subjects: 0
Study: 26467901

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous, unfractionated bone marrow
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo intervention: infusion of autologous blood
Number of subjects: 80
Study: 23385110

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP) - two 1-hour training sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group - single socialization contact
Number of subjects: 20
Study: 20628897

Group type: EXPERIMENTAL
Intervention: Forced sex with one partner
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Forced sex with 2+ partners
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: High number of partners with strong tendency to drink alcohol before sex
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Unprotected sex with a nonspousal partner and > 20 days of alcohol consumption in the last 30 days
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Discussion about family violence with larger social networks
Number of subjects: 522
Study: 20041782

Group type: EXPERIMENTAL
Intervention: Yeast hydrolysate (YH) administered for 2 weeks
Number of subjects: 0
Study: 18605225

Group type: EXPERIMENTAL
Intervention: COLD-fX (immune-modulator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REMEMBER-fX (neuro-modulator)
Number of subjects: 0
Study: 15234398

Group type: EXPERIMENTAL
Intervention: HDB tirofiban (25 microg/kg/3 min, and infusion of 0.15 microg/kg/min for 24 to 48 h)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HDB tirofiban
Number of subjects: 202
Study: 11163738

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 9052467

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 8378292

Group type: EXPERIMENTAL
Intervention: DA Salbutamol/DNCG (0.1 mg Salbutamol and 1.0 mg DNCG/puff)
Number of subjects: 20

Group type: COMPARATOR
Intervention: DA Salbutamol alone (0.1 mg Salbutamol puff)
Number of subjects: 20
Study: 3527070

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide and droperidol (regimen I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Regimen II
Number of subjects: 24
Study: 31470006

Group type: EXPERIMENTAL
Intervention: Small-intestinal-release peppermint oil (182 mg)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Ileocolonic-release peppermint oil (182 mg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both peppermint oil groups
Number of subjects: 190
Study: 30129316

Group type: EXPERIMENTAL
Intervention: Ludloff osteotomy assisted with a 3D printed navigation template
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional Ludloff osteotomy
Number of subjects: 28
Study: 26929955

Group type: COMPARATOR
Intervention: Conventional method (Ni-Cr)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CAD/CAM system (iTero/industrial milling)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CAD/CAM system (3S/industrial milling)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CAD/CAM system (Cerec Bluecam/industrial milling)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CAD/CAM system (Cerec BlueCam/Sirona milling)
Number of subjects: 50
Study: 24879304

Group type: EXPERIMENTAL
Intervention: Switched to consuming Orbs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tobacco abstinent
Number of subjects: 4

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dual use of cigarettes and Orbs
Number of subjects: 4
Study: 21207506

Group type: EXPERIMENTAL
Intervention: Biofeedback activated (using a tilt sensor on the trunk)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biofeedback inactivated
Number of subjects: 20
Study: 20516031

Group type: EXPERIMENTAL
Intervention: DMARD monotherapy
Number of subjects: 9052

Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 9052
Study: 18982929

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16092581

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion, 300 mg/d
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 12585148

Group type: EXPERIMENTAL
Intervention: Danxiaoling Pill (DXLP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Composite Yiganling (Control)
Number of subjects: 58
Study: 11869855

Group type: EXPERIMENTAL
Intervention: Intracoronary estrogen administration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide (glyburide)
Number of subjects: 50
Study: 10731736

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 143

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 143
Study: 7924241

Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Individual Treatment (IT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Static Control Group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Individual Treatment (Rehearsal IT)
Number of subjects: 113
Study: 2573963

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Antacids and cholinolytics
Number of subjects: 142
Study: 4840431

Group type: EXPERIMENTAL
Intervention: Buffered cephalothin solution
Number of subjects: 13

Group type: COMPARATOR
Intervention: Unbuffered cephalothin solution
Number of subjects: 13